Purchase this article with an account.
J. Guerrero-Naranjo, M. A. Martínez-Castellanos, V. Kon-Jara, M. Gordon, M. Torres-Soriano, A. Solis-Vivanco, N. Salazar-Teran, J. Fromow-Guerra, H. Quiroz-Mercado; Experience of 18 Months in the Use of Intravitreal Bevacizumab in a Single Ophtalmology Center. Invest. Ophthalmol. Vis. Sci. 2007;48(13):95.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the stadistics on an 18 months experience in the use of Bevacizumab in single opthalmology center (Asociacion para Evitar la Ceguera en Mexico).
A retrospective study was done of clinicals records od 1918 intravitreal injections.
We found 1005 female patients, 913 male patients. The injections were distribuited as follows: Diabetic Retinopathy and Diabetic Macular Edema 814, Age Related Macular Edema 704, Occlusion Vein Branch 207, Central Vein Occlusion 108, Retinopathy of Prematury 22, Choroidal Neovascularization not related to Age-Related Macular Degeneration 44, Uveitis 12, Voght Koyanagi Harada 2, Central Serous Coroidopathy 4, Von Hippel Lindau 2, Choroid Hemangioma 2. We did not found any systemic complication. We found four patients with proliferative diabetic retinopathy developed, tractional retinal detachment (TRD). Three cases of endophtalmitis, one rhegmatogenous retinal detachment, and one vitreous hemorrhage were also observed.
The antiangiogenic therapy with Bevacizumab is safe, and has different applications in a wide variety of proliferative retinal disseases.
This PDF is available to Subscribers Only